MedPath

AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China

Not Applicable
Completed
Conditions
Peripheral Artery Disease
Interventions
Procedure: common PTA balloon catheter
Procedure: DEB catheter
Registration Number
NCT02137577
Lead Sponsor
Acotec Scientific Co., Ltd
Brief Summary

The purpose of this study is to determine whether DEB is more effective than common PTA balloon using under in long-term vessel patency and inhibiting restenosis in the infrapopliteal artery.

Detailed Description

PTA is an established alternative to open surgical bypass for the treatment of infrainginual disease of critical limb ischemia.

DEBs are designed to promote arterial patency by reducing neointimal proliferation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Age between 18 and 85 years
  • Patients with peripheral artery disease (PAD), with Rutherford classification between 4 and 6
  • an occlusion or a minimum grade of stenosis Primary over 70% in the below popliteal artery
  • The expected survival time is more than 1 year
  • signed Patient informed consent form
Exclusion Criteria
  • Serum creatinine clearance rate less than 30ml/min in patients
  • patients with acute thrombosis requiring lysis or thrombectomy
  • patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
  • patient requiring intervention in both lower limbs at the same time
  • In-stent restenosis in the blow-knee popliteal artery
  • target lesion can't be cross by the guide wire
  • the stenosis rate of proximal outflow more than 30% with or without intervention
  • the length of the stenosis or occlusion in proximal outflow(including the Iliac artery, the superficial femoral artery, the Popliteal artery) more than 150mm before intervention
  • stenosis or occlusion of distal outflow for below-the-ankle artery.
  • expected major amputations at the index limb before intervention
  • known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
  • patients participating in another clinical trials with interfere with this trial in the same time
  • pregnancy and lactating woman
  • untreatable bleeding diatheses

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
common PTA balloon cathetercommon PTA balloon catheteruse common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
DEB catheterDEB catheteruse DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
Primary Outcome Measures
NameTimeMethod
Primary Patency [Time Frame: 6 months]6 months

Freedom from target vessel occlusion and clinically driven target lesion reintervention

Secondary Outcome Measures
NameTimeMethod
Ulcer healing rate6 months, 12 months

Healed or not, if not, improving,stagnant, worsening

device success rateduring the operation(after using the DEB catheter)

DEB catheter can reach the target lesions, expand as expected(not broken), and withdraw successfully.

technical success ratesduring the operation(after using the DEB catheter)

The blood supply of the target lesion recovered after treatment, and residual stenosis less than 50%

if occured clinically driven TLR( target lesion revascularization)6 months, 12 months,18 months, 24 months

Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as: resting pain occur again, ulcer deterioration, new foot ulcers

target lesion late lumen loss 6 months6 months

measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months

Ulcer healing time6 months, 12 months, 18 months, 24 months

Healed or not

operation success rateduring the operation(after using the DEB catheter)

both device succeed and technical succeed, and without clinical complication

limb salvage in surviving subjects30 days, 6 months, 12 months,18 months, 24 months

No Amputation of target limb

Change from baseline ankle brachial index(ABI) at 6 months6 months

measure ankle brachial index

\>1.3 Vascular wall calcification is severe

0.9\~1.1 Normal range

0.5\~0.8 Mild and moderate ischemia of lower limb arteries

\<0.5 severe ischemia

change from baseline Rutherford stage at 6 months6 months, 12 months,18 months, 24 months

based the following definition of Rutherford stage, evaluate the stage of patient. Then compare the stage of patient just after procedure and 6 months after treatment

Stage clinical symptom

0 asymptomatic

1. mild claudication

2. moderate claudication

3. severe claudication

4. ischemic rest pain

5. minor tissue loss

6. ulceration or gangrene

Trial Locations

Locations (11)

People's Liberation Army General Hospital

🇨🇳

BeiJing, China

The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

🇨🇳

Shanghai, China

Xiyuan Hospital, China Academy of Chinese Medical Sciences

🇨🇳

Beijing, China

Peking Union Medical College Hospital

🇨🇳

Beijing, China

Xuanwu Hospital, Capital Medical University

🇨🇳

Beijing, China

The First Affiliated Hospital of Dalian Medical University

🇨🇳

Dalian, China

The First Affiliated Hospital, Sun Yat-sen University

🇨🇳

Guangzhou, China

Renji Hospital, Shanghai Jiaotong University School of Medicine

🇨🇳

Shanghai, China

The Second Hospital of Hebei Medical University

🇨🇳

Shijiazhuang, China

Shengjing Hospital of China Medical University

🇨🇳

Shenyang, China

Tianjin Medical University General Hospital

🇨🇳

Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath